Ustekinumab for Refractory Colitis Associated with Immune Checkpoint Inhibitors

N Engl J Med. 2021 Feb 11;384(6):581-583. doi: 10.1056/NEJMc2031717.
No abstract available

Publication types

  • Letter

MeSH terms

  • Colitis, Ulcerative / drug therapy*
  • Colitis, Ulcerative / etiology
  • Female
  • Humans
  • Immune Checkpoint Inhibitors / adverse effects*
  • Interleukin-12 / antagonists & inhibitors
  • Interleukin-23 / antagonists & inhibitors
  • Male
  • Middle Aged
  • Ustekinumab / therapeutic use*

Substances

  • Immune Checkpoint Inhibitors
  • Interleukin-23
  • Interleukin-12
  • Ustekinumab